Samsung Bioepis Outlines European Eculizumab Roll-Out
Epysqli Rival To Soliris Is First Biosimilar Solely Commercialized By Firm In Europe
Executive Summary
Samsung Bioepis has offered details on the launch of its Epysqli eculizumab biosimilar rival to Soliris in European markets.